scispace - formally typeset
Y

Yves Pommier

Researcher at National Institutes of Health

Publications -  847
Citations -  65543

Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.

Papers
More filters
Journal ArticleDOI

3-Hydroxypyrimidine-2,4-diones as an Inhibitor Scaffold of HIV Integrase

TL;DR: These studies support an antiviral mechanism of dual inhibition against both IN and RT and validate 3-hydroxypyrimidine-2,4-diones as an IN inhibitor scaffold.
Journal ArticleDOI

Design, synthesis, and biological evaluation of cytotoxic 11-aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline topoisomerase I inhibitors

TL;DR: Despite an imperfect correlation between cytotoxicities and topoisomerase I inhibition results, the hypothetical structural model of the cleavage complex presented here provides a conceptual framework to explain the structure-activity relationships.
Journal ArticleDOI

Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2)

TL;DR: The discovery of isoquinoline-1,3-dione as a viable chemotype for selectively inhibiting TDP2 may provide a platform toward understanding TDP1 as a drug target.
Journal ArticleDOI

Human apurinic/apyrimidinic endonuclease (Ape1) and its N-terminal truncated form (AN34) are involved in DNA fragmentation during apoptosis.

TL;DR: It is found that Ape1 itself preferentially cleaves damaged chromatin DNA isolated from cells treated with apoptotic stimuli and that silencing of Ape 1 expression decreases apoptotic DNA fragmentation in DFF40/CAD-deficient cells.
Journal ArticleDOI

Effects of DNA methylation on topoisomerase I and II cleavage activities.

TL;DR: Results suggest an interaction of topoisomerase I with the DNA major grove at positions -3 and -4, which may have profound effects on the activity ofTopoisomerases and may alter the distribution of cleavage sites produced by anticancer drugs in chromatin.